David A. Siegel 4 D Molecular Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 126,400 shares of FDMT stock, worth $572,592. This represents 0.0% of its overall portfolio holdings.
Number of Shares
126,400
Previous 22,900
451.97%
Holding current value
$572,592
Previous $247,000
185.02%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding FDMT
# of Institutions
147Shares Held
46.7MCall Options Held
121KPut Options Held
33.2K-
Black Rock Inc. New York, NY4.9MShares$22.2 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.56MShares$20.7 Million0.41% of portfolio
-
Goldman Sachs Group Inc New York, NY4.27MShares$19.4 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY2.95MShares$13.4 Million2.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.86MShares$13 Million0.0% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $147M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...